{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.144","value":"1.487"},{"groupId":"OG001","spread":"0.688","value":"2.387"},{"groupId":"OG002","spread":"1.151","value":"2.115"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"description":"Xerostomia will also be assessed by measurement of stimulated saliva production posttreatment.","dispersionType":"Standard Deviation","groups":[{"description":"Subjects were administered a 7 mg loading dose subcutaneously followed by a 3.5 mg maintenance dose subcutaneously twice a week while on concurrent cisplatin and RT.","id":"OG000","title":"Phase 1: Group 1"},{"description":"Subjects were administered a 14 mg loading dose subcutaneously followed by a 7 mg maintenance dose subcutaneously twice a week while on concurrent cisplatin and RT.","id":"OG001","title":"Phase 1: Group II"},{"description":"Subjects were administered a 28 mg loading dose subcutaneously followed by a 14 mg maintenance dose subcutaneously twice a week while on concurrent cisplatin and RT.","id":"OG002","title":"Phase 2: Group III"}],"paramType":"MEAN","populationDescription":"one subject in group 3 did not complete follow up and was excluded from analysis","reportingStatus":"POSTED","timeFrame":"6 months","title":"Incidence of Radiation-induced Xerostomia by Stimulated Saliva Production","type":"SECONDARY","unitOfMeasure":"gram"}